Metastatic Carcinoma PDX Models

Suitable preclinical models such as patient-derived xenografts (PDX) are needed to evaluate drugs specifically targeting metastatic carcinoma. PDX models are known to be the most predictive preclinical model for evaluating an agent’s efficacy prior to entering the clinic. More

PDX offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, PDX models reflect the heterogeneity and diversity of the human patient population. PDX give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials. CrownBio’s HuPrime® PDX models are well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.
MC0665Metastatic CarcinomaSCCVIEW MODEL
MC1392Metastatic CarcinomaNAVIEW MODEL
MC1454Metastatic CarcinomaNAVIEW MODEL
MC2296Metastatic CarcinomaNAVIEW MODEL
MC3050Metastatic CarcinomaNAVIEW MODEL
MC3084Metastatic CarcinomaNAVIEW MODEL
MC3128Metastatic CarcinomaSCCVIEW MODEL
MC3160Metastatic CarcinomaSCCVIEW MODEL
MC3161Metastatic CarcinomaNAVIEW MODEL
MC3359Metastatic CarcinomaAdenocarcinomaVIEW MODEL